Fosfomycin Calcium Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fosfomycin Calcium Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
58
Registered trials
6
Result records
28
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fosfomycin Calcium Hydrate can convert its Small molecule drug profile and Peptidoglycan biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fosfomycin Calcium Hydrate (query alias: fosfomycin) |
|---|---|
| Modality / target | Small molecule drug; Peptidoglycan; Peptidoglycan inhibitors, Cell wall inhibitors |
| Highest global status | Approved |
| Originator | Shaanxi Aoxing Pharmaceutical Co., Ltd. |
| Active developers | Meiji Seika Pharma Co., Ltd., Harbin Guokang Pharmaceutical Co Ltd |
The MCP disease footprint includes Urinary Tract Infections, Infectious enteritis, Complicated skin and skin structure infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07063095 | Phase 3 | Recruiting | 100 | Time in hours from first study-medication administration to normalization of all qSOFA parameters and decrease of peak CRP by 50%. |
| JPRN-jRCT2071260030 | Phase 1/2 | 募集中 | 32 | Phase 1b -Safety and tolerability of MGT-006 (adverse events, adverse reactions) Phase 2a -Safety and tolerability of MGT-006 (adverse events, adverse reactions) |
| JPRN-jRCTs031250169 | Phase 1/2 | Recruiting | 20 | Clinical Response Rate at Week 8 After FMT Treatment. Clinical response is defined as a decrease of 3 or more points from baseline in the Harvey-Bradshaw Index (HBI). |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial
Phase 3; n=166; evaluation: Negative. Reported fields: Colonized by multidrug resistant Gram-negative bacteria = 11.0 % ; Colonized by multidrug resistant Gram-negative bacteria = 3.0 %
Diarrhoea as a frequent adverse event after intramuscular ertapenem treatment for uncomplicated <i>Neisseria gonorrhoeae</i> : a secondary analysis from the NABOGO trial
Phase 3; n=343; evaluation: Negative. Reported fields: Diarrhea = 10.7 % ; Diarrhea = 50.5 % ; Diarrhea = 2.0 %
Single Dose Monurol for Treatment of Acute Cystitis
Not Applicable; n=300; evaluation: not stated. Reported fields: Number of Participants Who Were Cured = 120 Participants ; Number of Participants Who Were Cured: P-Value = <0.001; Number of Participants Who Were Cured: P-Value = <0.001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fosfomycin Calcium Hydrate addresses Urinary Tract Infections, Infectious enteritis, Complicated skin and skin structure infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 28 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Peptidoglycan records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2025-08-07 | CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team | Approved | US$300.0M upfront; US$25.0M milestones; US$325.0M stated total |
| 2025-08-04 | Cumberland Pharmaceuticals Receives Vizient Contract For New Vibativ® 4-Vial Starter Pak | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Olefin epoxidase and application thereof in preparation of fosfomycin”. The milestone feed surfaced a patent-application signal described as “Associations of fosfomycin and colistin for use against biofilm-associated bacterial infections”. The milestone feed surfaced a patent-application signal described as “Preparation method of fosfomycin calcium”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
